Utility of ERG versus AMACR expression in diagnosis of minimal adenocarcinoma of the prostate in needle biopsy tissue

American Journal of Surgical Pathology

Volumn 38, Issue 7, 2014, Pages 1007-1012

  Andrews, Caitlin ^a   Humphrey, Peter A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

carcinoma; diagnosis; ERG; immunohistochemistry; prostate

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; ERG PROTEIN, HUMAN; ISOMERASE; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; COMPARATIVE STUDY; ENZYMOLOGY; EVALUATION STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSTATE TUMOR; RETROSPECTIVE STUDY;

ADENOCARCINOMA; BIOPSY, NEEDLE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; RETROSPECTIVE STUDIES; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902537161     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000205     Document Type: Article

References (34)

1. Epstein JI. Diagnosis of limited adenocarcinoma of the prostate. Histopathology. 2012;60: 28-40.
2. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy. J Clin Pathol. 2007;60: 35-42.
3. Brimo F, Epstein JI. Immunohistochemical pitfalls in prostate pathology. Hum Pathol. 2012;43: 313-324.
4. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol. 2005;22: 88-104.
5. Shah RB. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management. Adv Anat Pathol. 2013;20: 117-124.
6. Rosen P, Sesterhenn IA, Brassell SA, et al. Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol. 2012;9: 131-137.
7. Van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011;24: 1128-1138.
8. Tomlins SA, Palanisamy N, Siddiqui J, et al. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med. 2012;136: 935-946.
9. Yaskiv O, Zhang X, Simmerman K, et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol. 2011;35: 1062-1068.
10. He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer". Am J Surg Pathol. 2011;35: 608-614.
11. Shah RB, Tadros Y, Brummell B, et al. The diagnostic use of ERG in resolving and "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and alphamethylacyl- CoA-racemase markers. Hum Pathol. 2013;44: 786-794.
12. Warrick JI, Humphrey PA. Foamy gland carcinoma of the prostate in needle biopsy. Incidence, Gleason grade, and comparative amethylacyl- CoA racemase vs. ERG expression. Am J Surg Pathol. 2013;37: 1709-1714.
13. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of prostatic carcinoma. Am J Surg Pathol. 2005;29: 1228-1242.
14. Epstein JI. An update of the Gleason Grading System. J Urol. 2010;183: 433-440.
15. Epstein JI, Humphrey PA. Acinar (usual) adenocarcinoma of the prostate. In: Epstein JI, Cubilla AL, Humphrey PA, eds. Tumors of the Prostate Gland, Seminal Vesicles, Penis, and Scrotum, Chapter 4. Washington, DC: American Registry of Pathology; 2011: 136-166.
16. Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol. 2002;26: 921-925.
17. Rubin MA, Zhou M, Dhanasekaran SM, et al. (Alpha)-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287: 1662-1670.
18. Beach R, Gown AM, de Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26: 1588-1596.
19. Jiang Z, Wu C-L, Woda BA, et al. P504S/alpha-methylacyl-CoA racemase. A useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26: 1169-1174.
20. Magi-Galluzzi C, Luo J, Issacs WB, et al. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small cancer foci on needle biopsy. Am J Surg Pathol. 2003;27: 1128-1133.
21. Jiang Z, Woda B, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25: 1397-1404.
22. Wu CL, Yang XJ, Tretiakova M, et al. Analysis of alphamethylacyl- CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol. 2004;35: 1008-1013.
23. Sanderson SO, Sebo TJ, Murphy LM, et al. An analysis of the p63/ alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays. Am J Clin Pathol. 2004;121: 22-225.
24. Molinie V, Fromont G, Sibony M, et al. Diagnostic utility of p63/ alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol. 2004;17: 1180-1190.
25. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63, alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol. 2005;29: 579-587.
26. Hameed O, Humphrey PA. P63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning. Am J Clin Pathol. 2005;124: 708-715.
27. Jiang Z, Li C, Fischer A, et al. Using an AMACR (P504S)/ 34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol. 2005;123: 231-236.
28. Herawi M, Parwani AV, Irie J, et al. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol. 2005;29: 299-302.
29. Adley BP, Yang XJ. Alpha-methylacyl coenzyme A racemase immunoreactivity in partial atrophy of the prostate. Am J Clin Pathol. 2006;126: 849-855.
30. Przybycin CG, Kunju LP, Wu AJ, et al. Partial atrophy in prostate needle biopsies: a detailed analysis of its morphology, immunophenotype, and cellular kinetics. Am J Surg Pathol. 2008;32: 58-64.
31. Skinnider BF, Oliva E, Young RH, et al. Expression of alphamethylacyl- CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. Am J Clin Pathol. 2004;28: 701-705.
32. Gupta A, Wang HL, Policarpio-Nicholas ML, et al. Expression of alpha-methylacyl coenzyme A racemase in nephrogenic adenoma. Am J Surg Pathol. 2004;28: 1224-1229.
33. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010;13: 228-237.
34. Hameed O, Humphrey PA. Immunohistochemical evaluation of prostate needle biopsies using saved interval sections vs. new recut sections from the block: a prospective comparison. Am J Clin Pathol. 2009;131: 683-687.